| Identification | Back Directory | [Name]
3'-N-ACETYLNEURAMIN-LACTOSE SODIUM SALT | [CAS]
128596-80-5 | [Synonyms]
3'-SL
3'-SIALYLLACTOSE
II3NEUAC,I3FUC-LAC
3'-Sialyllactose (sodium)
3'-SIALYLLACTOSE SODIUM SALT
NEU5AC-ALPHA2-3GAL-BETA1-4GLC
MONOFUCOSYL, MONOSIALYLLACTOSE
3'-Sialyllactose Sodium Salt >
3'-N-ACETYLNEURAMIN-LACTOSE SODIUM SALT
3'-Sialyllactose Sodium Salt (synthetic)
3'-Sialyllactose Sodium Salt from human milk
Neu5Ac alpha(2-3)Gal beta(1-4)Glc Sodium Salt
ALPHA-NEU5AC-[2->3]-BETA-D-GAL-[1->4]-D-GLC SODIUM SALT
α-NeuNAc-(2→3)-β-D-Gal-(1→4)-D-Glc 3′-N-Acetylneuraminyl-D-lactose sodium salt
O-(N-Acetyl-alpha-neuraminosyl)-(2-3)-O-beta-D-galactopyranosyl-(1-4)-D-glucose monosodium salt
Sodium (2S,4S,5R,6R)-5-acetamido-2-(((2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-(((2R,3R,4R,5R)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl)oxy)tetrahydro-2H-pyran-4-yl)oxy)-4-hydroxy-6-((1R,2R)-1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylate | [Molecular Formula]
C23H38NNaO19 | [MDL Number]
MFCD00166999 | [MOL File]
128596-80-5.mol | [Molecular Weight]
655.53 |
| Chemical Properties | Back Directory | [Melting point ]
>180oC (dec.) | [storage temp. ]
−20°C
| [solubility ]
Methanol (Slightly, Heated), Water (Slightly) | [form ]
Solid | [color ]
White to Off-White | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
3''-Sialyllactose binds several viral strains, including strains of influenza, HIV-1, reovirus, and polyomavirus. | [in vivo]
3'-Sialyllactose sodium (10-100 mg/kg; p.o. three times a week for 6 weeks) protects mice against cartilage destruction from osteoarthritis[1].
3'-Sialyllactose sodium (500, 1000 and 2000 mg/kg; oral administration; once) induces no micronuclei in the bone marrow cells of mice[3].
3'-Sialyllactose sodium (oral administration; (500 to 1000 to 2000 mg/kg) every dose at 4-day intervals) shows the maximum tolerance dose (MTD) is greater than 2000 mg/kg in male and female beagle dogs[3].
3'-Sialyllactose sodium shows a lethal dose (LD50) above 20 g/kg bw, the highest dose tested[3]. | Animal Model: | 8-week-old male C57BL/6 mice with medial meniscus surgery[1] | | Dosage: | 10, 50 and 100 mg/kg | | Administration: | Oral gavage; 10-100 mg/kg three times a week; for 6 weeks | | Result: | Effectively protected osteoarthritis mice against cartilage destruction by catabolic factor expression.
|
|
|
|